COLUMBIA, MD., Jan. 27 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (NASDAQ:MATK) announced today that Wal-Mart has introduced a new DHA-enriched product to its private label infant formula line. The new formula, Parent's Choice with a blend of LIPIDS, is supplemented with Martek's proprietary blend of plant-derived docosahexaenoic acid (DHA) and arachidonic acid (ARA).
DHA and ARA, two nutrients that are key building blocks of an infant's brain and visual system, are naturally present in breast milk. Clinical studies have demonstrated numerous benefits for those infants receiving DHA and ARA-supplemented formula. Martek's DHA and ARA are the only sources of these nutrients that have been reviewed by the United States Food and Drug Administration (FDA) and cleared for use in U.S. infant formula.
"The public demand for DHA- and ARA-supplemented formulas in the US has been incredible," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek. "In less than a year, 10 formulas containing Martek's oils have been introduced in the U.S. with great success."
Wal-Mart's Parent's Choice infant formula line is manufactured by Wyeth Nutritionals, Inc. and distributed by PBM Products, Inc. Wal-Mart's Parent's Choice with a blend of LIPIDS formula is now available in Wal-Mart stores nationwide.
Currently, infant formulas containing Martek's oil blend are sold in over 60 countries by various infant formula manufacturers that are licensees of Martek. In the U.S., infant formulas containing Martek's oils are also offered by Mead Johnson (Enfamil(R) LIPIL(R)) and Abbott Laboratories' Ross Products Division (Similac(R) Advance(R)).
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.